Development and validation of a UPLC-MS/MS method for the quantification of asciminib and its pharmacokinetic interaction and metabolic stability with shikonin
Abstract Asciminib has been approved for use in patients with chronic myeloid leukemia (CML) in the chronic phase. Shikonin has multiple pharmacological effects and is a mixed inhibitor of CYP450 enzymes. In clinical practice, the combination of asciminib and shikonin may lead to drug interactions....
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMC
2025-11-01
|
| Schriftenreihe: | BMC Pharmacology and Toxicology |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1186/s40360-025-01049-0 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|